Physician profile
Amy Hicks
NPI 1023350618
$4,012.12
in general payments reported to CMS, 2019-2025
31 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,082 · 2022: $784 · 2023: $1,037 · 2024: $810 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,146.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $510.40 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $439.56 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $436.66 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Merz North America, INC. | $390.49 | 2021-2023 | Xeomin |
| Abbvie INC. | $325.60 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.53 | 2021-2025 | Synjardy, Tradjenta, Jardiance |
| Revance Therapeutics, INC. | $241.21 | 2024-2025 | Daxxify |
| Astellas Pharma US INC | $240.63 | 2021-2024 | Veozah |
| Pfizer INC. | $195.75 | 2021-2025 | |
| Amgen INC. | $167.69 | 2021-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $117.98 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.67 | 2021-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $63.84 | 2021-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $63.50 | 2021-2022 | |
| Abbott Laboratories | $56.07 | 2021-2024 | Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $41.76 | 2022-2023 | Unithroid |
| Kowa Pharmaceuticals America, INC. | $37.00 | 2021-2023 | Livalo, Seglentis |
| Teva Pharmaceuticals USA, INC. | $33.39 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $31.98 | 2021 | |
| Emd Serono, INC. | $25.72 | 2021 | |
| Shield Therapeutics INC | $22.83 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.41 | 2024 | Xifaxan, Trulance |
| Neurocrine Biosciences, INC. | $19.49 | 2025 | |
| Axsome Therapeutics, INC. | $19.43 | 2023 | Auvelity |
| Exact Sciences Corporation | $18.61 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $18.21 | 2024 | Quviviq |
| Sumitomo Pharma America, INC. | $16.36 | 2024 | Gemtesa |
| Esperion Therapeutics, INC. | $15.21 | 2024 | Nexletol |
| Glaxosmithkline, LLC. | $14.01 | 2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.27 | 2024 | Caplyta |
| Almatica Pharma LLC | $12.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.